Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings (Q37064021)

18 August 2017

1 reference

title

Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings (English)

1 reference

18 August 2017

1 reference

P Jeffrey Conn

1

1 reference

18 August 2017

Bryan L Roth

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

23 January 2008

1 reference

18 August 2017

Neuropsychopharmacology

1 reference

18 August 2017

33

1 reference

18 August 2017

2048-2060

1 reference

18 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301638

18 August 2017

0 references

cites work

Meta-analytical studies on new antidepressants.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

21 January 2018

Mining the receptorome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

NIH Molecular Libraries Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Metabotropic glutamate receptors in the basal ganglia motor circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

REELIN and schizophrenia: a disease at the interface of the genome and the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The efficiency of multi-target drugs: the network approach might help drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Muscarinic receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The human polyomavirus, JCV, uses serotonin receptors to infect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Biological spectra analysis: Linking biological activity profiles to molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Biospectra analysis: model proteome characterizations for linking molecular structure and biological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Drug discovery: playing dirty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Population-based and family-based association study of 5'UTR polymorphism of the reelin gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Reelin promoter hypermethylation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Psychiatry in the genomics era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Small-dose ketamine improves the postoperative state of depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Catching up on schizophrenia: natural history and neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Disruption of two novel genes by a translocation co-segregating with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Designed multiple ligands. An emerging drug discovery paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Finding new tricks for old drugs: an efficient route for public-sector drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Discovery of an ectopic activation site on the M(1) muscarinic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

In psychosis, cortical interneurons overexpress DNA-methyltransferase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Use of selective serotonin reuptake inhibitors in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

Association study of the DISC1/TRAX locus with schizophrenia in a Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

7 January 2021

Selective inhibition of calcium entry induced by benzylisoquinolines in rat smooth muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

7 January 2021

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

7 January 2021

A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

7 January 2021

Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301638

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301638

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference